Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple ...

Eli Lilly (NYSE:LLY) said compounded weight-loss treatments that combine vitamin B12 with the active ingredient used in its ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could ...

Eli Lilly warns risks of compounded tirzepatide with B12 due to impurities that may cause toxicity and immune reactions, ...

Eli Lilly warns compounded tirzepatide mixed with B12 may contain impurities and safety risks as FDA tightens GLP-1 rules—get ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. In April 2025, the U.S. Food and Drug Administration ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to ...

A Henry County pharmacy was placed on probation after medication errors led to the hospitalization of three children in 2024.